Cancer Treatment Reviews
Volume 29, Supplement 1 , Pages 11-19, May 2003

The tumor microenvironment: focus on myeloma

  • William S Dalton

      Affiliations

    • Corresponding Author InformationCorrespondence to: William S. Dalton, PhD, MD, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA. Tel.: 1-813-615-4257; Fax: 1-813-615-4258

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Abstract 

A wide variety of cellular responses that may afford tumor cells drug-tolerance characteristics. Overexpression of plasma membrane efflux pumps, up-regulation of anti-apoptosis factors, down-regulation of proapoptosis factors, subcellular redistribution of drug targets, and up-regulation of detoxifying enzymes are just a few known mechanisms of cancer cell resistance. In addition to these individual cell adaptations, cellular drug resistance also appears to be mediated by the binding of tumor cells to extracellular matrix (ECM) proteins. Cell adhesion-mediated drug resistance (CAM-DR) is particularly relevant in hematologic malignancies such as multiple myeloma, where myeloma cells localize in the bone marrow and interact with stroma and stromal cells, initiating the production of proteins that stimulate or support tumor survival. Thus, CAM-DR provides a plausible explanation for the protective mechanisms associated with myeloma cell adhesion and demonstrates that the tumor microenvironment may hold the key to elucidating how tumor cells resist chemotherapy.

Keywords:  Drug resistance, cell adhesion, myeloma, fibronectin

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0305-7372(03)00077-X

doi:10.1016/S0305-7372(03)00077-X

Cancer Treatment Reviews
Volume 29, Supplement 1 , Pages 11-19, May 2003